Embed Size (px)
Citation preview
NOVEDADES EN EL TRATAMIENTO DEL
VIH
Miguel Ángel Rodríguez Sagrado
Hospital Ramón y Cajal
Servicio de Farmacia
20 de Octubre de 2017
CONFLICTO DE INTERESES
• He realizado ponencias para Janssen, Sandoz, Gilead, MerckSerono, Biogen, Abbvie, ViiV y MSD.
• Los donantes no han influido, más allá de los aspectos formales, a la elaboración y comunicación de los resultados científicos ni ponencias.
• Situación actual
• ¿Cuándo tratamos?
• ¿Con qué tratamos?
• Fármacos disponibles
• ¿Qué nos espera?
• Nuevos fármacos de viejas familias
• Nuevos fármacos de nuevas familias
• Nuevas estrategias
• Administración prolongada
• Biterapias
• PREGUNTAS
Situación actual
•Situación actual:¿Cuándo tratamos?
•Situación actual:¿Cuándo tratamos?
Situación actual:¿Cuándo tratamos? START: Primary Endpoint
N Engl J Med 2015; 373:795-807August 27, 2015DOI: 10.1056/NEJMoa1506816
N Engl J Med 2015; 373:795-807August 27, 2015DOI: 10.1056/NEJMoa1506816
•Situación actual:¿Con qué tratamos?
•Situación actual: ¿Con qué tratamos?. Recomendaciones DHHS2016
•Situación actual: ¿Con qué tratamos?. Recomendaciones GESIDA2017
Preferred
Regimens that have shown superior efficacy to their comparators in randomized clinical trials or that, having show non-inferiority, present advantages of good tolerability, low toxicity and low risk of pharmacological interactions. They can be given to most patients.
• ABC/3TC + DTG
• TFV/FTC + DTG
• TFV/FTC + RAL
• TFV/FTC/EVGc
•Situación actual: ¿Con qué tratamos?. IAS-USA Guidelines, 2016
•Situación actual: fármacos disponibles
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Fusion inhibitors
Enfuvirtide
Entry Inhibitors
Maraviroc
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
¿Qué nos espera?
•¿Qué le pedimos a un TAR óptimo?
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Máxima eficacia virológica: CV <50 copias/mL en 85% (ITT)
•Excelente tolerancia: suspensiones por EA <5% a 48 semanas
•No toxicidad a largo plazo: no lipoatrofia, hiperlipidemia (otros: RCV, hueso, riñón)
•No selección de resistencias: no resistencias cruzadas. Fácilmente rescatable
•Comodidad de administración: pocas dosis, comprimidos y requerimientos
•Precio
•¿Qué puede mejorarse respecto al TAR actual?
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Eficacia virológica: probablemente no
•Resistencia: área de mejora limitada
•Tolerabilidad: globalmente, no. Algunos aspectos de algunos fármacos
•Toxicidad a largo plazo: posiblemente no
•Comodidad: más STR, administración prolongada
•Coste
Nuevos Fármacos Viejas Familias
•Nuevos fármacos viejas familias: fármacos disponibles
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Fusion inhibitors
Enfuvirtide
Entry Inhibitors
Maraviroc
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: NNRTIs
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
Doravirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Fusion inhibitors
Enfuvirtide
Entry Inhibitors
Maraviroc
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
•Nuevos fármacos viejas familias: NNRTIs DORAVIRINA
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Alta eficacia incluso ante variantes resistentes a otros NNRTIs
•Metabolismo por el CYP3A4 (no es indutor ni inhibidor)
•Dosis única diaria sin requerimientos nutricionales
•No interacciones con IBPs
•Nuevos fármacos viejas familias: NNRTIs DORAVIRINA
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
DORAVIRINA vs Darunavir/r
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
•Nuevos fármacos viejas familias: NNRTIs DORAVIRINA
DORAVIRINA vs Darunavir/r
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
22
42
76 83 86 84
15
38
71 81 81 80
0
20
40
60
80
100
0 4 8 12 16 20 24 28 32 36 40 44 48
% o
f P
arti
cip
ants
(9
5%
CI)
Treatment Week
DOR DRV+r
Difference (95% CI): 3.9% (-1.6%, 9.4%)
•Nuevos fármacos viejas familias: NNRTIs DORAVIRINA
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
Source: Molina JM, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 45LB.
•Nuevos fármacos viejas familias: fármacos disponibles
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Fusion inhibitors
Enfuvirtide
Entry Inhibitors
Maraviroc
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: INIs
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
Doravirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Bictegravir
Fusion inhibitors
Enfuvirtide
Entry Inhibitors
Maraviroc
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
•Nuevos fármacos viejas familias: INIs BICTEGRAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Estructuralmente relacionado con dolutegravir
•Alta eficacia incluso ante muchos sutipos de VIH-1 y VIH-2
•Baja citotoxicidad
•t1/2=19 h: Dosis única diaria
•EC fase III en marcha
•Nuevos fármacos viejas familias: INIs BICTEGRAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: INIs BICTEGRAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: INIs BICTEGRAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: INIs RALTEGRAVIR QD
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Una vez al día
•2 comprimidos de 600 mg
•Disponible en diciembre 2017 o enero 2018
•Nuevos fármacos viejas familias: fármacos disponibles
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Fusion inhibitors
Enfuvirtide
Entry Inhibitors
Maraviroc
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: inhibidores de la entrada
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Entry Inhibitors
Maraviroc
Fostemsavir
Ibalizumab
Pro140
UB-421
NRTIs
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
NNRTIs
Delavirdine
Efavirenz
Etravirine
Nevirapine
Nevirapine XR
Rilpivirine
Doravirine
PIs
Atazanavir
Darunavir
Fosamprenavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
INIs
Raltegravir
Dolutegravir
Elvitegravir
Bictegravir
Fusion inhibitors
Enfuvirtide
PK Boosters
Ritonavir
Cobicistat
STR
Atripla
Eviplera
Stribild
Triumeq
Genvoya
•Nuevos fármacos viejas familias: inhibidores de la entrada
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: IBALIZUMAB
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: PRO 140
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: UB 421
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: FOSTEMSAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: FOSTEMSAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: FOSTEMSAVIR
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos viejas familias: COMBOS VARIOS
• Rilpivirina+emtricitabina+TAF
• Rilpivirina+dolutegravir
• Varios fármacos con 3TC
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Nuevos Fármacos Nuevas Familias
•Nuevos fármacos nuevas familias: inhibidores de la maduración
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos nuevas familias: inhibidores de la maduración
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos nuevas familias: inhibidores de la cápside
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos nuevas familias: inhibidores de la cápside
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevos fármacos nuevas familias: inhibidores de la cápside GS-CA1
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Actúa a nivel picomolar •EC50 de DTG: 1.200 pM •EC50 de GS-CA1: 140 pM
Unión a región muy conservada
Mutantes con escasa capacidad replicativa Posibilidad de formulación “long-acting”
1 inyección sc mensual
•Nuevos fármacos viejas y nuevas familias
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Doravirina: •Perfil de resistencias distinto, mejor tolerabilidad •Tratamiento de inicio, ¿simplificación?, ¿rescate?
Bictegravir: •Tratamiento de inicio, ¿simplificación?, ¿rescate? •Nuevo STR
Inh. de la entrada: •Tratamiento de rescate. •Posibilidad administración prolongada
Inh. Maduración: • Interrumpido desarrollo
Inh. Cápside: •Administración prolongada
Nuevas Estrategias
Nuevas Estrategias: Administración prolongada
•Nuevas estrategias: administración prolongada: Cabotegravir + Rilpivirine
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevas estrategias: administración prolongada: Cabotegravir + Rilpivirine
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevas estrategias: administración prolongada: Cabotegravir + Rilpivirine
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
LATTE-2 Week 32 Primary Endpoint: HIV-1 RNA <50 c/mL by Snapshot (ITT-ME)
•Nuevas estrategias: administración prolongada: MK-8591
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Reducción de C.V. tras 10 mg (oral)
•Nuevas estrategias: administración prolongada: MK-8591
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
MK-8591 parenteral formulations release for >180 days
Nuevas Estrategias: Biterapias
•Nuevas estrategias: biterapias
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
•Nuevas estrategias: biterapias
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
SWORD-1 and SWORD-2 Phase III Study Design
•Nuevas estrategias: biterapias
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
SWORD-1 and SWORD-2 Snapshot Outcomes at Week 48
Conclusiones
•Conclusiones
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetic Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Adapted from http://www.aidsmeds.com/list.shtml and each product’s eMC SPC available at http://www.medicines.org.uk/emc/search
Tratamiento Antirretroviral Actual •Excelencia en todas las características
Futuro
•Nuevos fármacos de viejas familias y nuevas familias de fármacos para satisfacer las necesidades no cubiertas •Fármacos de administración parenteral y de acción prolongada (administración cada 2, 3, 6 o 12 meses) •Reducción del número de fármacos
• PREGUNTAS
